Sanara MedTech Inc. (SMTI): Price and Financial Metrics

Sanara MedTech Inc. (SMTI): $37.97

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add SMTI to Watchlist
Sign Up

SMTI Price/Volume Stats

Current price $37.97 52-week high $50.18
Prev. close $37.97 52-week low $26.06
Day low $37.30 Volume 8,100
Day high $38.78 Avg. volume 13,068
50-day MA $37.89 Dividend yield N/A
200-day MA $36.43 Market Cap 324.19M

SMTI Stock Price Chart Interactive Chart >

SMTI POWR Grades

  • Sentiment is the dimension where SMTI ranks best; there it ranks ahead of 95.25% of US stocks.
  • SMTI's strongest trending metric is Stability; it's been moving up over the last 26 weeks.
  • SMTI ranks lowest in Momentum; there it ranks in the 4th percentile.

SMTI Stock Summary

  • For SMTI, its debt to operating expenses ratio is greater than that reported by just 19.89% of US equities we're observing.
  • With a year-over-year growth in debt of 1,268.1%, SANARA MEDTECH INC's debt growth rate surpasses 99.13% of about US stocks.
  • Revenue growth over the past 12 months for SANARA MEDTECH INC comes in at 66.71%, a number that bests 93.27% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to SMTI, based on their financial statements, market capitalization, and price volatility, are CRWS, PEGY, ASTE, ISDR, and UBFO.
  • Visit SMTI's SEC page to see the company's official filings. To visit the company's web site, go to www.wndm.com.

SMTI Valuation Summary

  • In comparison to the median Healthcare stock, SMTI's price/sales ratio is 154.55% higher, now standing at 5.6.
  • SMTI's price/sales ratio has moved down 3.9 over the prior 243 months.

Below are key valuation metrics over time for SMTI.

Stock Date P/S P/B P/E EV/EBIT
SMTI 2023-12-29 5.6 7.9 -42.9 -45.3
SMTI 2023-12-28 5.7 8.0 -43.5 -45.8
SMTI 2023-12-27 5.6 8.0 -43.1 -45.5
SMTI 2023-12-26 5.5 7.7 -41.9 -44.2
SMTI 2023-12-22 5.2 7.4 -40.0 -42.2
SMTI 2023-12-21 5.3 7.5 -40.9 -43.1

SMTI Growth Metrics

    The 2 year revenue growth rate now stands at 110.44%.
  • Its 3 year net cashflow from operations growth rate is now at -13769.68%.
  • The 5 year cash and equivalents growth rate now stands at 657.25%.
SMTI's revenue has moved up $17,177,949 over the prior 15 months.

The table below shows SMTI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 37.55998 -6.694212 -11.39348
2022-06-30 30.33935 -6.485426 -11.94339
2022-03-31 26.94571 -5.6654 -9.869494
2021-12-31 24.14392 -4.814526 -7.921914
2021-09-30 21.89965 -3.621237 -4.620099
2021-06-30 20.38203 -2.898222 -3.746955

Sanara MedTech Inc. (SMTI) Company Bio


Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. It offers CellerateRX Surgical Activated Collagen Adjuvant and HemaQuell Resorbable Bone Hemostat. The company was founded in 1982 and is headquartered in Fort Worth, TX.


SMTI Latest News Stream


Event/Time News Detail
Loading, please wait...

SMTI Latest Social Stream


Loading social stream, please wait...

View Full SMTI Social Stream

Latest SMTI News From Around the Web

Below are the latest news stories about SANARA MEDTECH INC that investors may wish to consider to help them evaluate SMTI as an investment opportunity.

Sanara MedTech Inc.'s (NASDAQ:SMTI) top owners are retail investors with 32% stake, while 31% is held by insiders

Key Insights The considerable ownership by retail investors in Sanara MedTech indicates that they collectively have a...

Yahoo | December 4, 2023

Sanara MedTech Inc. Announces the Publication of a 5,335 Patient Study Demonstrating a Significant Reduction in Surgical Site Infections When Activated Collagen (CellerateRX® Surgical Powder) Was Used to Promote Wound Healing

FORT WORTH, TX, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that the Journal of Surgery has published a retrospective study on CellerateRX® Surgica

Yahoo | November 30, 2023

Sanara MedTech Inc. Reports Record Sales in Q3 2023 with Narrowed Net Loss and Positive ...

Strategic Acquisitions and Product Launches Propel Growth Amidst Operational Challenges

Yahoo | November 13, 2023

Sanara MedTech Inc. Announces Third Quarter 2023 Results

FORT WORTH, TX, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today its strategic, operational and financial results for the quarter ended September 30, 20

Yahoo | November 13, 2023

Sanara MedTech Inc. Announces Third Quarter Earnings Release and Conference Call Dates

FORT WORTH, TX, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today details for the release of its results for the quarter ended September 30, 2023. Sanara

Yahoo | October 30, 2023

Read More 'SMTI' Stories Here

SMTI Price Returns

1-mo 8.45%
3-mo 15.73%
6-mo 2.37%
1-year -9.10%
3-year 8.80%
5-year 743.78%
YTD -7.62%
2023 -9.67%
2022 53.98%
2021 -40.78%
2020 209.94%
2019 392.35%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!